Abbott Laboratories (ABT) Revenue — Quarter Ended Jun 30, 2025
Revenue for the quarter increased compared with both the immediately preceding quarter and the same quarter one year earlier. The filing includes management discussion and liquidity information, but the reported figures alone show the growth.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue for the quarter increased compared with both the immediately preceding quarter and the same quarter one year earlier. The filing includes management discussion and liquidity information, but the reported figures alone show the growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11.1B
Revenue reported for this quarter.
Quarter-over-quarter
+7.6%
Change from the immediately preceding quarter.
Year-over-year
+7.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$43.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $10.6B | +4.9% |
| Dec 31, 2024 | $11B | +7.2% |
| Mar 31, 2025 | $10.4B | +4.0% |
| Jun 30, 2025 | $11.1B | +7.4% |
Revenue performance
The sequential increase was similar in magnitude to the year-over-year increase, indicating steady performance. The filing notes higher segment operating earnings in the cash flow discussion, though the revenue growth is based on the reported numbers.
Quarterly comparison
After a decline in the prior quarter, revenue rebounded in the current quarter to a level above the previous peak. The current quarter's revenue also exceeded the level from the same period a year ago.
What to watch
The filing indicates a decrease in cash and cash equivalents and an increase in working capital, driven by debt repayment and inventory growth, which are factors to monitor in subsequent periods.